UNSPSC 51182048: Bolandiol dipropionate

This classification denotes an anabolic steroid with the molecular formula C24H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 595CNE7RHB, chemically known as 4-estrene-3-beta,17-beta-diol 3,17-dipropionate but more generally known as bolandiol dipropionate, which bears US NIH Compound Identifier 16141. Most nations, for tariff and trade purposes, schedule bolandiol dipropionate under HS 29061900 and SITC 51231. As of Q4 2014, BOLANDIOL DIPROPIONATE remains US FDA's Preferred Term for this commodity.

Bolandiol dipropionate bears US NLM identifiers UMLS ID C3266850 and NCI Concept Code C87452. SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@@H]4OC(=O)CC)C.

UNSPSC 51182048 Bolandiol dipropionate is a Commodity code that describes a specific pharmaceutical active pharmaceutical ingredient supplied through state and local cooperative purchasing agreements for distribution across participating government facilities. State and local governments procure bolandiol dipropionate and related generic multi-source pharmaceuticals through cooperative purchasing arrangements rather than direct vendor relationships, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving as a representative issuing body. The scope of work involves manufacturers providing comprehensive pharmaceutical products with certified National Drug Codes (NDC), SKUs, UPCs, and full product specifications to authorized wholesalers for distribution to state agencies, local government facilities, and participating jurisdictions. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), and offer flexible pricing through multiple formats including flat price, net price, or WAC-minus structures. Insurance requirements include commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000, with all products subject to FDA requirements and minimum six-month shelf-life stipulations.

The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted a Request for Proposal on January 20, 2026 with a proposal due date of March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products spanning Minnesota and Oregon. Evaluation will weight price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative fee compliance, EDI capability, and pricing-format agreement. The contract term runs two years for new responders with optional extensions at MMCAP's discretion, with awarded vendors effective July 1, 2026. No specific award values or budget ceilings are disclosed in the solicitation materials, though vendors should anticipate a 3 percent administrative fee on all purchases and performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures.